BILL ANALYSIS

HR7902

NEUTRAL

To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.

HR7902 (To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.) has been assessed with a neutral outlook for investors. This legislation directly affects Pfizer ($PFE) and $TEVA. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR 7902 is early-stage legislation with very low near-term passage probability (6 cosponsors, no committee action)

Revenue exposure to $PFE and $TEVA is immaterial — less than 0.1% of annual revenue for either company

$TEVA's 15% weekly gain and $PFE's 5% monthly decline are driven by company-specific catalysts, not abortion legislation

No federal spending is authorized — funding_amount is $0

How HR7902 Affects the Market

This bill has negligible market implications. $PFE at $26.71 (near 52-week low of $21.97) faces headwinds from LoE on Xeljanz, Ibrance, and Eliquis patent cliffs — not from a low-revenue product like mifepristone. $TEVA at $35.26 (near 52-week high of $37.35) is rallying on positive pipeline news and AJOVY/COPAXONE generic defense. Traders should not factor HR 7902 into positions on either stock. The only scenario that would change the market calculus is a surprise markup or hearing scheduling that signals bill progression — currently no evidence of that.

Bill Details

Metric	Value
Bill Number	HR7902
Market Sentiment	neutral
Event Date	March 12, 2026
Affected Sectors	Healthcare
Affected Stocks	Pfizer ($PFE), $TEVA
Source	View on Congress.gov →

Summary

HR 7902 (Safeguarding Women from Chemical Abortion Act) would withdraw FDA approval for mifepristone for pregnancy termination and create a federal tort for harm from chemical abortion drugs. The bill was introduced March 12, 2026, referred to two committees, and is in early legislative stages with only 6 cosponsors. Revenue exposure for $PFE and $TEVA is immaterial to their overall financials — less than 0.1% of revenue for each. The bill has effectively no near-term market impact.

Full AI Market Analysis

HR 7902 was introduced in the House on March 12, 2026 by Representative Harshbarger (R-TN) with 6 cosponsors. It has been referred to the Committee on Energy and Commerce and the Committee on the Judiciary. A companion bill (S4066) has been introduced in the Senate and referred to HELP Committee. The bill is in very early legislative stages — neither committee has held hearings or marked up the bill. Passage probability in the 119th Congress is low given the limited cosponsor support, divided government context, and the fact that similar bills have not advanced in prior sessions. The bill operates through two mechanisms: (1) deeming the FDA-approved application for mifepristone for pregnancy termination withdrawn after 14 days of enactment, making introduction into interstate commerce a violation of the FD&C Act; (2) establishing a federal tort cause of action for women harmed by chemical abortion drugs. The bill does not authorize or appropriate any federal spending — funding_amount_usd is $0. Structural winners and losers: There are no material winners from this bill. The only identified losers are $PFE and $TEVA, which manufacture branded and generic mifepristone respectively. However, the US mifepristone market for pregnancy termination (the relevant portion) is estimated at approximately $30-50M annually — a rounding error for Pfizer's $58B+ and Teva's $16B in annual revenue. Neither company has meaningful dependence on this product line. Real market data analysis: $PFE is trading at $26.71, down -1.11% over 7 days and -4.91% over 30 days. The stock has been declining from $27.56 on April 17 to $26.70 on April 30. This decline is attributable to broader pharma sector trends (patent cliff concerns, pipeline readouts) — not to this bill. $TEVA is trading at $35.26, up +15.08% over 7 days and +17.07% over 30 days, driven by positive late-stage trial data for olanzapine LAI and generic launch timelines — not related to mifepristone legislation. Remaining legislative path: The bill must pass through two House committees (Energy & Commerce; Judiciary) before a floor vote, then clear the Senate (where companion S4066 faces similar hurdles), then be signed by the President. No hearings are scheduled. Given the early stage and limited momentum, realistic timeline for any movement would be late 2026 at the earliest, if at all.